

Brett S Carver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/79096/publications.pdf>

Version: 2024-02-01

80
papers

10,059
citations

109264

35
h-index

66879

78
g-index

83
all docs

83
docs citations

83
times ranked

14004
citing authors

#	ARTICLE	IF	CITATIONS
1	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	1.9	8
2	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. <i>Nature Communications</i> , 2021, 12, 5053.	5.8	14
3	Rapid interrogation of cancer cell of origin through CRISPR editing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	12
4	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	1.5	10
5	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	7.7	135
6	Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. <i>Cancer Research</i> , 2020, 80, 1428-1437.	0.4	8
7	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	0.8	11
8	Regenerative potential of prostate luminal cells revealed by single-cell analysis. <i>Science</i> , 2020, 368, 497-505.	6.0	165
9	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. <i>Journal of Clinical Investigation</i> , 2020, 130, 5924-5941.	3.9	29
10	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 101-102.	0.2	0
11	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	47
12	Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1577-1586.	1.9	13
13	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.	0.5	6
14	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 458-467.	1.2	61
15	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	0.5	12
16	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.	0.5	7
17	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. <i>Journal of Experimental Medicine</i> , 2018, 215, 159-175.	4.2	121
18	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. <i>ELife</i> , 2018, 7, .	2.8	217

#	ARTICLE	IF	CITATIONS
19	Malignant Mesothelioma of the Tunica Vaginalis Testis: Outcomes Following Surgical Management Beyond Radical Orchiectomy. <i>Urology</i> , 2017, 107, 166-170.	0.5	16
20	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	0.5	12
21	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. <i>Nature Communications</i> , 2017, 8, 1081.	5.8	16
22	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.2	10
23	Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2016, 29, 431-432.	7.7	14
24	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	2.0	27
25	An allelic series of miR-17a ^{1/492} mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron. <i>Nature Genetics</i> , 2015, 47, 766-775.	9.4	101
26	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , 2015, 5, 550-563.	7.7	24
27	Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 343-346.	0.8	6
28	Late Relapse of Testicular Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 359-368.	0.8	31
29	Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 278-288.	1.9	29
30	Feedback Suppression of PI3K ^{1±} Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K ² . <i>Cancer Cell</i> , 2015, 27, 109-122.	7.7	203
31	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.2	20
32	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3082-3096.	2.5	27
33	Strategies for targeting the androgen receptor axis in prostate cancer. <i>Drug Discovery Today</i> , 2014, 19, 1493-1497.	3.2	18
34	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	13.5	1,184
35	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.2	49
36	Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. <i>Molecular Oncology</i> , 2014, 8, 1355-1364.	2.1	51

#	ARTICLE	IF	CITATIONS
37	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. <i>Nature Medicine</i> , 2013, 19, 1023-1029.	15.2	251
38	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. <i>Nature Genetics</i> , 2013, 45, 739-746.	9.4	134
39	Translating insights of AR signaling from mouse models. <i>Translational Andrology and Urology</i> , 2013, 2, 197-201.	0.6	0
40	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.	0.5	5
41	Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. <i>BJU International</i> , 2012, 110, 950-955.	1.3	8
42	The Role of Lymphadenectomy for Testicular Cancer: Indications, Controversies, and Complications. <i>Urologic Clinics of North America</i> , 2011, 38, 439-449.	0.8	11
43	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.	0.5	14
44	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.	0.5	10
45	Retroperitoneal Histologic Findings of Patients With Elevated Serum Alpha-fetoprotein and Pure Seminoma at Orchiectomy. <i>Urology</i> , 2011, 78, 844-847.	0.5	7
46	Postchemotherapy surgery for germ cell tumors of the testis. <i>Current Opinion in Oncology</i> , 2011, 23, 271-274.	1.1	3
47	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 575-586.	7.7	1,026
48	Integrative Genomic Profiling of Human Prostate Cancer. <i>Cancer Cell</i> , 2010, 18, 11-22.	7.7	3,151
49	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	2.0	25
50	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435.	0.5	47
51	Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor. <i>Indian Journal of Urology</i> , 2010, 26, 102.	0.2	2
52	Management of post-chemotherapy extra-retroperitoneal residual masses. <i>World Journal of Urology</i> , 2009, 27, 489-492.	1.2	27
53	ETS rearrangements and prostate cancer initiation. <i>Nature</i> , 2009, 457, E1-E1.	13.7	98
54	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. <i>Nature Genetics</i> , 2009, 41, 619-624.	9.4	595

#	ARTICLE	IF	CITATIONS
55	Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. <i>Nature Genetics</i> , 2009, 41, 524-526.	9.4	428
56	Preservation of Ejaculation in Patients Undergoing Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer. <i>Urology</i> , 2009, 73, 328-331.	0.5	117
57	The Case for Cytoreductive Nephrectomy for the Management of Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 182, 833-834.	0.2	0
58	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.	2.0	22
59	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529.	0.8	107
60	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608.	0.8	92
61	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369.	0.8	132
62	Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037.	0.8	99
63	Adult and Pediatric Testicular Teratoma. <i>Urologic Clinics of North America</i> , 2007, 34, 245-251.	0.8	39
64	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , 2007, 109, 528-535.	2.0	73
65	Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer. <i>Journal of Urology</i> , 2006, 176, 564-568.	0.2	212
66	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2006, 176, 100-104.	0.2	70
67	African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. <i>BJU International</i> , 2006, 98, 783-787.	1.3	43
68	Mouse Modeling in Oncologic Preclinical and Translational Research. <i>Clinical Cancer Research</i> , 2006, 12, 5305-5311.	3.2	60
69	449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2006, 175, 145-146.	0.2	5
70	Germ Cell Tumors of the Testis. <i>Annals of Surgical Oncology</i> , 2005, 12, 871-880.	0.7	47
71	Cleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. <i>BJU International</i> , 2005, 95, 509-512.	1.3	32
72	The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. <i>Nature Reviews Urology</i> , 2005, 2, 330-335.	1.4	14

#	ARTICLE	IF	CITATIONS
73	Late relapse of testicular germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 441-445.	0.8	36
74	Ureteral Injury Due to Penetrating Trauma. Southern Medical Journal, 2004, 97, 462-464.	0.3	18
75	RACE IS NOT A PREDICTOR OF PROSTATE CANCER DETECTION ON REPEAT PROSTATE BIOPSY. Journal of Urology, 2004, 172, 1853-1855.	0.2	12
76	The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen. Journal of Urology, 2003, 169, 589-591.	0.2	83
77	The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. Journal of Urology, 2003, 169, 589-91.	0.2	47
78	Large granular cell tumor of the penis in a 53-year-old man with coexisting prostate cancer. Urology, 2002, 59, 602.	0.5	5
79	Treatment Of Chronic Prostatitis Lowers Serum Prostate Specific Antigen. Journal of Urology, 2002, 167, 1723-1726.	0.2	115
80	Clinical stage T1c prostate cancer: Pathologic outcomes following radical prostatectomy in black and white men. Prostate, 2002, 50, 236-240.	1.2	16